Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson's disease

Neurobiology of Disease

Volumn 109, Issue , 2018, Pages 249-257

  Rocha, Emily M ^a   De Miranda, Briana ^a   Sanders, Laurie H ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; MITOCHONDRIAL PROTEIN; TUBULIN;

CELL ACTIVATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; GENE; GENE MUTATION; HUMAN; IMMUNE RESPONSE; LEWY BODY; MICROGLIA; MITOCHONDRIAL DYNAMICS; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; PROTEIN TRANSPORT; REVIEW; SNCA GENE; ANIMAL; GENETICS; INFLAMMATION; METABOLISM; MITOCHONDRION; PATHOLOGY;

ALPHA-SYNUCLEIN; ANIMALS; HUMANS; INFLAMMATION; MITOCHONDRIA; MITOCHONDRIAL DISEASES; PARKINSON DISEASE;

EID: 85017414324     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2017.04.004     Document Type: Review

References (185)

1. Alim, M.A., et al. Tubulin seeds alpha-synuclein fibril formation. J. Biol. Chem. 277 (2002), 2112–2117.
2. Alvarez-Erviti, L., et al. Chaperone-mediated autophagy markers in Parkinson disease brains. Arch. Neurol. 67 (2010), 1464–1472.
3. Anderson, J.P., et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 281 (2006), 29739–29752.
4. Appel-Cresswell, S., et al. Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. Mov. Disord. 28 (2013), 811–813.
5. Banerjee, K., et al. Alpha-synuclein induced membrane depolarization and loss of phosphorylation capacity of isolated rat brain mitochondria: implications in Parkinson's disease. FEBS Lett. 584 (2010), 1571–1576.
6. Barrett, P.J., Greenamyre, J.T., Post-translational modification of alpha-synuclein in Parkinson's disease. Brain Res. 1628 (2015), 247–253.
7. Bartels, T., et al. alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477 (2011), 107–110.
8. Bayer, T.A., et al. Alpha-synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease beta-amyloid plaque cores. Neurosci. Lett. 266 (1999), 213–216.
9. Bayir, H., et al. Peroxidase mechanism of lipid-dependent cross-linking of synuclein with cytochrome C: protection against apoptosis versus delayed oxidative stress in Parkinson disease. J. Biol. Chem. 284 (2009), 15951–15969.
10. Bender, A., et al. TOM40 mediates mitochondrial dysfunction induced by alpha-synuclein accumulation in Parkinson's disease. PLoS One., 8, 2013, e62277.
11. Betarbet, R., et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3 (2000), 1301–1306.
12. Beyer, K., Mechanistic aspects of Parkinson's disease: alpha-synuclein and the biomembrane. Cell Biochem. Biophys. 47 (2007), 285–299.
13. Binolfi, A., et al. Recognition between a short unstructured peptide and a partially folded fragment leads to the thioredoxin fold sharing native-like dynamics. Proteins 80 (2012), 1448–1464.
14. Bodner, C.R., et al. Multiple tight phospholipid-binding modes of alpha-synuclein revealed by solution NMR spectroscopy. J. Mol. Biol. 390 (2009), 775–790.
15. Braak, H., et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24 (2003), 197–211.
16. Braak, H., et al. Development of alpha-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson's disease. Acta Neuropathol. 114 (2007), 231–241.
17. Burre, J., et al. Properties of native brain alpha-synuclein. Nature, 498, 2013 (E4-6; discussion E6-7).
18. Camilleri, A., et al. Mitochondrial membrane permeabilisation by amyloid aggregates and protection by polyphenols. Biochim. Biophys. Acta. 1828 (2013), 2532–2543.
19. Cannon, J.R., et al. A highly reproducible rotenone model of Parkinson's disease. Neurobiol. Dis. 34 (2009), 279–290.
20. Cannon, J.R., et al. Expression of human E46K-mutated alpha-synuclein in BAC-transgenic rats replicates early-stage Parkinson's disease features and enhances vulnerability to mitochondrial impairment. Exp. Neurol. 240 (2013), 44–56.
21. Cartelli, D., et al. alpha-Synuclein is a Novel Microtubule Dynamase. Sci. Rep., 6(33289), 2016.
22. Chalfant, C.E., et al. Long chain ceramides activate protein phosphatase-1 and protein phosphatase-2A Activation is stereospecific and regulated by phosphatidic acid. J. Biol. Chem., 274, 1999 (20313–7).
23. Chen, L., Feany, M.B., Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat. Neurosci. 8 (2005), 657–663.
24. Chen, M., et al. Age- and brain region-dependent alpha-synuclein oligomerization is attributed to alterations in intrinsic enzymes regulating alpha-synuclein phosphorylation in aging monkey brains. Oncotarget. 7 (2016), 8466–8480.
25. Chinta, S.J., et al. Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neurosci. Lett. 486 (2010), 235–239.
26. Choi, B.K., et al. Large alpha-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking. Proc. Natl. Acad. Sci. USA 110 (2013), 4087–4092.
27. Chu, C.T., et al. Cardiolipin externalization to the outer mitochondrial membrane acts as an elimination signal for mitophagy in neuronal cells. Nat. Cell. Biol. 15 (2013), 1197–1205.
28. Colla, E., et al. Accumulation of toxic alpha-synuclein oligomer within endoplasmic reticulum occurs in alpha-synucleinopathy in vivo. J. Neurosci. 32 (2012), 3301–3305.
29. Cuervo, A.M., Dice, J.F., Age-related decline in chaperone-mediated autophagy. J. Biol. Chem., 275, 2000 (31505–13).
30. Cuervo, A.M., Dice, J.F., Regulation of lamp2a levels in the lysosomal membrane. Traffic 1 (2000), 570–583.
31. Cuervo, A.M., et al. Selective degradation of annexins by chaperone-mediated autophagy. J. Biol. Chem., 275, 2000 (33329–35).
32. Cuervo, A.M., et al. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305 (2004), 1292–1295.
33. Danzer, K.M., et al. Different species of alpha-synuclein oligomers induce calcium influx and seeding. J. Neurosci. 27 (2007), 9220–9232.
34. Dauer, W., et al. Resistance of alpha - synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl. Acad. Sci. USA 99 (2002), 14524–14529.
35. De Miranda, B.R., Van, Houten B., Sanders, L.H., Mitochondrial Mechanisms of Degeneration and Repair in Parkinson's Disease. 2016.
36. Dettmer, U., et al. In vivo cross-linking reveals principally oligomeric forms of alpha-synuclein and beta-synuclein in neurons and non-neural cells. J. Biol. Chem. 288 (2013), 6371–6385.
37. Dettmer, U., et al. Parkinson-causing alpha-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation. Nat. Commun., 6, 2015, 7314.
38. Devi, L., et al. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J. Biol. Chem. 283 (2008), 9089–9100.
39. Di Maio, R., et al. alpha-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson's disease. Sci. Transl. Med., 8, 2016 (342ra78).
40. Diao, J., et al. Native alpha-synuclein induces clustering of synaptic-vesicle mimics via binding to phospholipids and synaptobrevin-2/VAMP2. Elife, 2, 2013, e00592.
41. Dickson, D.W., Parkinson's disease and parkinsonism: neuropathology. Cold Spring Harb. Perspect. Med., 2, 2012.
42. Dobrowsky, R.T., et al. Ceramide activates heterotrimeric protein phosphatase 2A. J. Biol. Chem. 268 (1993), 15523–15530.
43. Du, T.T., et al. GBA deficiency promotes SNCA/alpha-synuclein accumulation through autophagic inhibition by inactivated PPP2A. Autophagy 11 (2015), 1803–1820.
44. Duda, J.E., et al. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann. Neurol. 52 (2002), 205–210.
45. Ellis, C.E., et al. Mitochondrial lipid abnormality and electron transport chain impairment in mice lacking alpha-synuclein. Mol. Cell Biol. 25 (2005), 10190–10201.
46. Emmanouilidou, E., et al. Cell-produced alpha-synuclein oligomers are targeted to, and impair, the 26S proteasome. Neurobiol. Aging 31 (2010), 953–968.
47. Erent, M., et al. S. pombe kinesins-8 promote both nucleation and catastrophe of microtubules. PLoS One, 7, 2012, e30738.
48. Fauvet, B., et al. alpha-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J. Biol. Chem. 287 (2012), 15345–15364.
49. Fornai, F., et al. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc. Natl. Acad. Sci. USA 102 (2005), 3413–3418.
50. Fortin, D.L., et al. Lipid rafts mediate the synaptic localization of alpha-synuclein. J. Neurosci. 24 (2004), 6715–6723.
51. Fry, M., Green, D.E., Cardiolipin requirement for electron transfer in complex I and III of the mitochondrial respiratory chain. J. Biol. Chem. 256 (1981), 1874–1880.
52. Fujiwara, H., et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4 (2002), 160–164.
53. Giasson, B.I., et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290 (2000), 985–989.
54. Giasson, B.I., et al. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J. Biol. Chem. 276 (2001), 2380–2386.
55. Glass, C.K., et al. Mechanisms underlying inflammation in neurodegeneration. Cell 140 (2010), 918–934.
56. Goedert, M., et al. Prion-like mechanisms in the pathogenesis of tauopathies and synucleinopathies. Curr. Neurol. Neurosci. Rep., 14, 2014, 495.
57. Goers, J., et al. Nuclear localization of alpha-synuclein and its interaction with histones. Biochemistry 42 (2003), 8465–8471.
58. Goldberg, A.L., Protein degradation and protection against misfolded or damaged proteins. Nature 426 (2003), 895–899.
59. Goncalves, S., Outeiro, T.F., Assessing the subcellular dynamics of alpha-synuclein using photoactivation microscopy. Mol. Neurobiol. 47 (2013), 1081–1092.
60. Gu, Z., et al. Nitrosative and oxidative stress links dysfunctional ubiquitination to Parkinson's disease. Cell Death Differ. 12 (2005), 1202–1204.
61. Gu, X.L., et al. Astrocytic expression of Parkinson's disease-related A53T alpha-synuclein causes neurodegeneration in mice. Mol. Brain., 3, 2010, 12.
62. Guardia-Laguarta, C., et al. alpha-Synuclein is localized to mitochondria-associated ER membranes. J. Neurosci. 34 (2014), 249–259.
63. Guerrero, E., et al. Recent advances in alpha-synuclein functions, advanced glycation, and toxicity: implications for Parkinson's disease. Mol. Neurobiol. 47 (2013), 525–536.
64. Hewett, S.J., et al. Interferon-gamma and interleukin-1 beta induce nitric oxide formation from primary mouse astrocytes. Neurosci. Lett. 164 (1993), 229–232.
65. Hoenen, C., et al. Alpha-synuclein proteins promote pro-inflammatory cascades in microglia: stronger effects of the A53T mutant. PLoS One., 11, 2016, e0162717.
66. Hoffmann, A., et al. Alpha-synuclein activates BV2 microglia dependent on its aggregation state. Biochem. Biophys. Res. Commun. 479 (2016), 881–886.
67. Houlden, H., Singleton, A.B., The genetics and neuropathology of Parkinson's disease. Acta Neuropathol. 124 (2012), 325–338.
68. Hsieh, C.H., et al. Functional impairment in miro degradation and mitophagy is a shared feature in familial and sporadic Parkinson's disease. Cell Stem Cell. 19 (2016), 709–724.
69. Hughes, A.J., et al. A clinicopathologic study of 100 cases of Parkinson's disease. Arch. Neurol. 50 (1993), 140–148.
70. Inglis, K.J., et al. Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system. J. Biol. Chem. 284 (2009), 2598–2602.
71. Jellinger, K., Neuropathological substrates of Alzheimer's disease and Parkinson's disease. J. Neural. Transm. Suppl. 24 (1987), 109–129.
72. Jensen, M.B., et al. Membrane curvature sensing by amphipathic helices: a single liposome study using alpha-synuclein and annexin B12. J. Biol. Chem. 286 (2011), 42603–42614.
73. Jiang, T., et al. P2X7 receptor is critical in alpha-synuclein–mediated microglial NADPH oxidase activation. Neurobiol. Aging 36 (2015), 2304–2318.
74. Kahle, P.J., et al. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha - synuclein in human and transgenic mouse brain. J. Neurosci. 20 (2000), 6365–6373.
75. Kamp, F., et al. Inhibition of mitochondrial fusion by alpha-synuclein is rescued by PINK1, Parkin and DJ-1. EMBO J. 29 (2010), 3571–3589.
76. Karpinar, D.P., et al. Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. EMBO J. 28 (2009), 3256–3268.
77. Kayed, R., et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300 (2003), 486–489.
78. Kiely, A.P., et al. Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation. Mol. Neurodegener., 10, 2015, 41.
79. Kim, C., et al. Non-cell-autonomous Neurotoxicity of alpha-synuclein Through Microglial Toll-like Receptor 2. Exp. Neurobiol. 25 (2016), 113–119.
80. Klionsky, D.J., Emr, S.D., Autophagy as a regulated pathway of cellular degradation. Science 290 (2000), 1717–1721.
81. Konno, T., et al. Autosomal dominant Parkinson's disease caused by SNCA duplications. Parkinsonism Relat. Disord. 22:Suppl. 1 (2016), S1–S6.
82. Kubo, S., et al. A combinatorial code for the interaction of alpha-synuclein with membranes. J. Biol. Chem. 280 (2005), 31664–31672.
83. Lashuel, H.A., et al. The many faces of alpha-synuclein: from structure and toxicity to therapeutic target. Nat. Rev. Neurosci. 14 (2013), 38–48.
84. Lee, H.J., et al. Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J. Biol. Chem. 277 (2002), 671–678.
85. Lee, H.J., et al. Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. J. Neurosci. 24 (2004), 1888–1896.
86. Lee, K.W., et al. Enhanced phosphatase activity attenuates alpha-synucleinopathy in a mouse model. J. Neurosci. 31 (2011), 6963–6971.
87. Li, L., et al. Human A53T alpha-synuclein causes reversible deficits in mitochondrial function and dynamics in primary mouse cortical neurons. PLoS One, 8, 2013, e85815.
88. Liu, G., et al. alpha-Synuclein is differentially expressed in mitochondria from different rat brain regions and dose-dependently down-regulates complex I activity. Neurosci. Lett. 454 (2009), 187–192.
89. Liu, G., et al. Increased oligomerization and phosphorylation of alpha-synuclein are associated with decreased activity of glucocerebrosidase and protein phosphatase 2A in aging monkey brains. Neurobiol. Aging 36 (2015), 2649–2659.
90. Loeb, V., et al. The transgenic overexpression of alpha-synuclein and not its related pathology associates with complex I inhibition. J. Biol. Chem. 285 (2010), 7334–7343.
91. Ludtmann, M.H., et al. Monomeric alpha-synuclein exerts a physiological role on brain ATP synthase. J. Neurosci. 36 (2016), 10510–10521.
92. Luth, E.S., et al. Soluble, prefibrillar alpha-synuclein oligomers promote complex I-dependent, Ca2 +-induced mitochondrial dysfunction. J. Biol. Chem. 289 (2014), 21490–21507.
93. Mak, S.K., et al. Lysosomal degradation of alpha-synuclein in vivo. J. Biol. Chem. 285 (2010), 13621–13629.
94. Manning-Bog, A.B., et al. Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism. Neurotoxicology 30 (2009), 1127–1132.
95. Mazzulli, J.R., et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146 (2011), 37–52.
96. Mbefo, M.K., et al. Phosphorylation of synucleins by members of the Polo-like kinase family. J. Biol. Chem. 285 (2010), 2807–2822.
97. McCormack, A.L., et al. Increased alpha-synuclein phosphorylation and nitration in the aging primate substantia nigra. Cell Death Dis., 3, 2012, e315.
98. McLean, P.J., et al. Subcellular localization of alpha-synuclein in primary neuronal cultures: effect of missense mutations. J Neural Transm. Suppl., 2000, 53–63.
99. Meredith, G.E., Rademacher, D.J., MPTP mouse models of Parkinson's disease: an update. J. Parkinsons Dis. 1 (2011), 19–33.
100. Middleton, E.R., Rhoades, E., Effects of curvature and composition on alpha-synuclein binding to lipid vesicles. Biophys. J. 99 (2010), 2279–2288.
101. Mileykovskaya, E., Dowhan, W., Cardiolipin-dependent formation of mitochondrial respiratory supercomplexes. Chem. Phys. Lipids. 179 (2014), 42–48.
102. Milner, R., Campbell, I.L., The extracellular matrix and cytokines regulate microglial integrin expression and activation. J. Immunol. 170 (2003), 3850–3858.
103. Morfini, G.A., et al. Axonal transport defects in neurodegenerative diseases. J. Neurosci. 29 (2009), 12776–12786.
104. Nakamura, K., et al. Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. J. Biol. Chem. 286 (2011), 20710–20726.
105. Neumann, M., et al. Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J. Clin. Invest. 110 (2002), 1429–1439.
106. Oueslati, A., et al. Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies. Prog. Brain Res. 183 (2010), 115–145.
107. Oueslati, A., et al. Polo-like kinase 2 regulates selective autophagic alpha-synuclein clearance and suppresses its toxicity in vivo. Proc. Natl. Acad. Sci. USA 110 (2013), E3945–E3954.
108. Ovadia, A., et al. Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys. Neurobiol. Aging 16 (1995), 931–937.
109. Pacher, P., et al. Nitric oxide and peroxynitrite in health and disease. Physiol. Rev. 87 (2007), 315–424.
110. Pankratz, N., Foroud, T., Genetics of Parkinson disease. Genet. Med. 9 (2007), 801–811.
111. Park, J.S., et al. Pathogenic effects of novel mutations in the P-type ATPase ATP13A2 (PARK9) causing Kufor-Rakeb syndrome, a form of early-onset parkinsonism. Hum. Mutat. 32 (2011), 956–964.
112. Park, H.J., et al. Dysregulation of protein phosphatase 2A in parkinson disease and dementia with lewy bodies. Ann. Clin. Transl. Neurol. 3 (2016), 769–780.
113. Paxinou, E., et al. Induction of alpha-synuclein aggregation by intracellular nitrative insult. J. Neurosci. 21 (2001), 8053–8061.
114. Perez-Revuelta, B.I., et al. Metformin lowers Ser-129 phosphorylated alpha-synuclein levels via mTOR-dependent protein phosphatase 2A activation. Cell Death Dis., 5, 2014, e1209.
115. Perlson, E., et al. Retrograde axonal transport: pathways to cell death?. Trends Neurosci. 33 (2010), 335–344.
116. Peterson, R.T., et al. Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein. Proc. Natl. Acad. Sci. USA 96 (1999), 4438–4442.
117. Polymeropoulos, M.H., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997), 2045–2047.
118. Porcari, R., et al. The H50Q mutation induces a 10-fold decrease in the solubility of alpha-synuclein. J. Biol. Chem. 290 (2015), 2395–2404.
119. Pronin, A.N., et al. Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J. Biol. Chem. 275 (2000), 26515–26522.
120. Prots, I., et al. alpha-Synuclein oligomers impair neuronal microtubule-kinesin interplay. J Biol Chem. 288 (2013), 21742–21754.
121. Qing, H., et al. Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications. Biochem. Biophys. Res. Commun. 387 (2009), 149–152.
122. Quinn, M.T., Gauss, K.A., Structure and regulation of the neutrophil respiratory burst oxidase: comparison with nonphagocyte oxidases. J. Leukoc. Biol. 76 (2004), 760–781.
123. Radford, R., et al. The degree of astrocyte activation in multiple system atrophy is inversely proportional to the distance to alpha-synuclein inclusions. Mol. Cell. Neurosci. 65 (2015), 68–81.
124. Ramirez, A., et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat. Genet. 38 (2006), 1184–1191.
125. Reeve, A.K., et al. Aggregated alpha-synuclein and complex I deficiency: exploration of their relationship in differentiated neurons. Cell Death Dis., 6, 2015, e1820.
126. Rideout, H.J., et al. alpha-synuclein is required for the fibrillar nature of ubiquitinated inclusions induced by proteasomal inhibition in primary neurons. J. Biol. Chem. 279 (2004), 46915–46920.
127. Rieker, C., et al. Neuropathology in mice expressing mouse alpha-synuclein. PLoS One, 6, 2011, e24834.
128. Roberts, R.F., et al. Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain. Brain 138 (2015), 1642–1657.
129. Rocha, E.M., et al. Sustained systemic glucocerebrosidase inhibition induces brain alpha-synuclein aggregation, microglia and complement C1q activation in mice. Antioxid. Redox. Signal. 23 (2015), 550–564.
130. van Rooijen, B.D., et al. Membrane binding of oligomeric alpha-synuclein depends on bilayer charge and packing. FEBS Lett. 582 (2008), 3788–3792.
131. Rose, S., et al. Age-related effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets. Eur. J. Pharmacol. 230 (1993), 177–185.
132. Ross, O.A., et al. Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann. Neurol. 63 (2008), 743–750.
133. Ryan, B.J., et al. Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease. Trends. Biochem. Sci. 40 (2015), 200–210.
134. Salvi, M., et al. Superiority of PLK-2 as alpha-synuclein phosphorylating agent relies on unique specificity determinants. Biochem. Biophys. Res. Commun. 418 (2012), 156–160.
135. Sanders, L.H., Greenamyre, J.T., Oxidative damage to macromolecules in human Parkinson disease and the rotenone model. Free Radic. Biol. Med. 62 (2013), 111–120.
136. Sanders, L.H., et al. Mitochondrial DNA damage: molecular marker of vulnerable nigral neurons in Parkinson's disease. Neurobiol. Dis. 70 (2014), 214–223.
137. Sato, H., et al. Authentically phosphorylated alpha-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease. J. Neurosci. 31 (2011), 16884–16894.
138. Sato, H., et al. The role of Ser129 phosphorylation of alpha-synuclein in neurodegeneration of Parkinson's disease: a review of in vivo models. Rev. Neurosci. 24 (2013), 115–123.
139. Schell, H., et al. Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice. Neuroscience 160 (2009), 796–804.
140. Shavali, S., et al. Mitochondrial localization of alpha-synuclein protein in alpha-synuclein overexpressing cells. Neurosci. Lett. 439 (2008), 125–128.
141. Sidransky, E., et al. Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology 73 (2009), 1424–1425 (author reply 1425-6).
142. Singleton, A.B., et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science, 302(841), 2003.
143. Smith, W.W., et al. Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J. Neurosci. 25 (2005), 5544–5552.
144. Song, D.D., et al. Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP. Exp. Neurol. 186 (2004), 158–172.
145. Song, L.K., et al. Targeted overexpression of alpha-synuclein by raav2/1 vectors induces progressive nigrostriatal degeneration and increases vulnerability to MPTP in mouse. PLoS One., 10, 2015, e0131281.
146. Soper, J.H., et al. Alpha-synuclein-induced aggregation of cytoplasmic vesicles in Saccharomyces cerevisiae. Mol. Biol. Cell. 19 (2008), 1093–1103.
147. Spillantini, M.G., et al. Alpha-synuclein in Lewy bodies. Nature 388 (1997), 839–840.
148. Strack, S., et al. Protein serine/threonine phosphatase 1 and 2A associate with and dephosphorylate neurofilaments. Brain Res. Mol. Brain Res. 49 (1997), 15–28.
149. Su, X., et al. Synuclein activates microglia in a model of Parkinson's disease. Neurobiol. Aging. 29 (2008), 1690–1701.
150. Subramaniam, S.R., et al. Region specific mitochondrial impairment in mice with widespread overexpression of alpha-synuclein. Neurobiol. Dis. 70 (2014), 204–213.
151. Sugeno, N., et al. Serine 129 phosphorylation of alpha-synuclein induces unfolded protein response-mediated cell death. J. Biol. Chem. 283 (2008), 23179–23188.
152. Takahashi, H., Wakabayashi, K., The cellular pathology of Parkinson's disease. Neuropathology 21 (2001), 315–322.
153. Tanner, C.M., et al. Rotenone, paraquat, and Parkinson's disease. Environ. Health Perspect. 119 (2011), 866–872.
154. Theillet, F.X., et al. Structural disorder of monomeric alpha-synuclein persists in mammalian cells. Nature 530 (2016), 45–50.
155. Tofaris, G.K., et al. Ubiquitin ligase Nedd4 promotes alpha-synuclein degradation by the endosomal-lysosomal pathway. Proc. Natl. Acad. Sci. USA. 108 (2011), 17004–17009.
156. Tsigelny, I.F., et al. Role of alpha-synuclein penetration into the membrane in the mechanisms of oligomer pore formation. FEBS J. 279 (2012), 1000–1013.
157. Van Laar, V.S., Berman, S.B., The interplay of neuronal mitochondrial dynamics and bioenergetics: implications for Parkinson's disease. Neurobiol. Dis. 51 (2013), 43–55.
158. Visanji, N.P., et al. Effect of Ser-129 phosphorylation on interaction of alpha-synuclein with synaptic and cellular membranes. J. Biol. Chem. 286 (2011), 35863–35873.
159. Vogiatzi, T., et al. Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J. Biol. Chem. 283 (2008), 23542–23556.
160. Volles, M.J., et al. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40 (2001), 7812–7819.
161. Volpicelli-Daley, L.A., Effects of alpha-synuclein on axonal transport. Neurobiol Dis., 2016.
162. Volpicelli-Daley, L.A., et al. Formation of alpha-synuclein Lewy neurite-like aggregates in axons impedes the transport of distinct endosomes. Mol. Biol. Cell 25 (2014), 4010–4023.
163. Wakamatsu, M., et al. Accumulation of phosphorylated alpha-synuclein in dopaminergic neurons of transgenic mice that express human alpha-synuclein. J. Neurosci. Res. 85 (2007), 1819–1825.
164. Wang, W., et al. A soluble alpha-synuclein construct forms a dynamic tetramer. Proc. Natl. Acad. Sci. USA 108 (2011), 17797–17802.
165. Wang, S., et al. alpha-Synuclein, a chemoattractant, directs microglial migration via H2O2-dependent Lyn phosphorylation. Proc. Natl. Acad. Sci. USA 112 (2015), E1926–E1935.
166. Wang, S., et al. Identification of a specific alpha-synuclein peptide (alpha-Syn 29-40) capable of eliciting microglial superoxide production to damage dopaminergic neurons. J. Neuroinflammation, 13, 2016, 158.
167. Wang, Y., et al. The novel mechanism of rotenone-induced alpha-synuclein phosphorylation via reduced protein phosphatase 2A activity. Int. J. Biochem. Cell Biol. 75 (2016), 34–44.
168. Wilkinson, B.L., Landreth, G.E., The microglial NADPH oxidase complex as a source of oxidative stress in Alzheimer's disease. J. Neuroinflammation, 3, 2006, 30.
169. Winklhofer, K.F., Haass, C., Mitochondrial dysfunction in Parkinson's disease. Biochim. Biophys. Acta 1802 (2010), 29–44.
170. Winner, B., et al. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc. Natl. Acad. Sci. USA 108 (2011), 4194–4199.
171. Wislet-Gendebien, S., et al. Cytosolic proteins regulate alpha-synuclein dissociation from presynaptic membranes. J. Biol. Chem. 281 (2006), 32148–32155.
172. Wu, J., et al. Lewy-like aggregation of alpha-synuclein reduces protein phosphatase 2A activity in vitro and in vivo. Neuroscience 207 (2012), 288–297.
173. Xie, W., Chung, K.K., Alpha-synuclein impairs normal dynamics of mitochondria in cell and animal models of Parkinson's disease. J. Neurochem. 122 (2012), 404–414.
174. Xilouri, M., et al. Boosting chaperone-mediated autophagy in vivo mitigates alpha-synuclein-induced neurodegeneration. Brain 136 (2013), 2130–2146.
175. Xilouri, M., et al. alpha-synuclein and protein degradation systems: a reciprocal relationship. Mol. Neurobiol. 47 (2013), 537–551.
176. Xilouri, M., et al. Impairment of chaperone-mediated autophagy induces dopaminergic neurodegeneration in rats. Autophagy 12 (2016), 2230–2247.
177. Yano, H., et al. Inhibition of mitochondrial protein import by mutant huntingtin. Nat. Neurosci. 17 (2014), 822–831.
178. Zhang, M., et al. Gluing the respiratory chain together Cardiolipin is required for supercomplex formation in the inner mitochondrial membrane. J. Biol. Chem. 277 (2002), 43553–43556.
179. Zhang, W., et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 19 (2005), 533–542.
180. Zhang, W., et al. Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein. Glia 55 (2007), 1178–1188.
181. Zhang, Q.S., et al. Pathological alpha-synuclein exacerbates the progression of Parkinson's disease through microglial activation. Toxicol. Lett. 265 (2017), 30–37.
182. Zharikov, A.D., et al. shRNA targeting alpha-synuclein prevents neurodegeneration in a Parkinson's disease model. J. Clin. Invest. 125 (2015), 2721–2735.
183. Zhou, R.M., et al. Molecular interaction of alpha-synuclein with tubulin influences on the polymerization of microtubule in vitro and structure of microtubule in cells. Mol. Biol. Rep. 37 (2010), 3183–3192.
184. Zhou, J., et al. Changes in the solubility and phosphorylation of alpha-synuclein over the course of Parkinson's disease. Acta Neuropathol. 121 (2011), 695–704.
185. Zigoneanu, I.G., et al. Interaction of alpha-synuclein with vesicles that mimic mitochondrial membranes. Biochim. Biophys. Acta 1818 (2012), 512–519.